ONSWIK KwikPen

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ONSWIK KwikPen
Generic name
INSULIN EFSITORA ALFA-GOBE
Manufacturer
Eli Lilly and Company
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
6e02229e-262c-4e25-9240-9e9de4eb7c1d
SPL ID
da30dc98-a2dc-4a7c-91e1-180ca496daa4
Version
2
Effective date
2026-09-23
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:17
Harmonized routes table
Harmonized routes
SUBCUTANEOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypoglycemia Due to Medication Errors and Accidental Overdose: Accidental mix-ups between insulin products can occur. Advise patients to always check the product label before each injection to confirm they are using ONSWIK and not another insulin or injectable antidiabetic medicine. Do not transfer ONSWIK into a syringe as overdosage and severe hypoglycemia can result. Do not repeat the one-time starting dose after the first injection. ( 5.1 ) Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to insulin dosage, co-administered glucose-lowering medications, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. ( 5.3 ) Hyperglycemia or Hypoglycemia with changes in insulin regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of glucose monitoring. ( 5.4 ) Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue ONSWIK, monitor and treat if indicated. ( 5.5 ) Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated. ( 5.6 ) Never share ONSWIK between patients, even if the needle is changed. ( 5.7 ) Fluid Retention and Heart Failure with Concomitant Use of PPAR-Gamma Agonists: Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation of the PPAR-gamma agonist if heart failure occurs. ( 5.8 ) 5.1 Hypoglycemia Due to Medication Errors and Accidental Overdose Serious hypoglycemia requiring hospitalization has occurred due to accidental mix-ups between once-weekly insulin products and other insulin products or once-weekly injectable antidiabetic medicines, incorrect dose selection, and dosing frequency errors. To avoid dosing errors when switching from daily basal insulin to ONSWIK, follow the dosage recommendations in the Dosage and Administration Section ( 2.4 ). Administer ONSWIK once weekly only. Do not repeat administration of the one-time starting dose. Advise patients to always check the product label before each injection to confirm they are using ONSWIK and not another insulin or injectable antidiabetic medicine. Prior to initiation, train patients and their caregiver(s) on how to select their weekly ONSWIK dosage. Advise patients using other injectable medications for glycemic control that the dosage selection of ONSWIK differs. Instruct patients to visually verify the dialed units on the dose window of the ONSWIK KwikPen before each injection to avoid dosing errors. Patients should not dial the maximum single dose (400 units for the U-500 KwikPen or 800 units for the U-1,000 KwikPen) of ONSWIK unless this is the prescribed dose Patients should not use a syringe to remove ONSWIK from the ONSWIK KwikPen. The markings on the syringe will not measure the dose correctly and this can result in overdosage and severe hypoglycemia [see Dosage and Administration ( 2.2 , 2.3 , 2.4 ), Instructions for Use] . Monitor patients for signs and symptoms of hypoglycemia, particularly during the first several weeks after initiation or dose escalation of ONSWIK. Ensure patients understand how to recognize and manage hypoglycemia [see Warnings and Precautions ( 5.3 )]. 5.2 Severe Hypoglycemia in Patients with Type 1 Diabetes Mellitus ONSWIK is not recommended for use in patients with type 1 diabetes mellitus due to increased risk of severe hypoglycemia. In a 52-week clinical trial of adults with type 1 diabetes mellitus, the incidence of Level 3 (severe) hypoglycemia was higher for patients treated with ONSWIK compared with insulin degludec (10% versus 3%). 5.3 Hypoglycemia Hypoglycemia is the most common adverse reaction associated with insulins, including ONSWIK [see Adverse Reactions ( 6.1 )] . Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )] , or in patients who experience recurrent hypoglycemia. The long-acting effect of ONSWIK may delay recovery from hypoglycemia compared to shorter-acting insulins [see Clinical Pharmacology ( 12.2 , 12.3 )] . Risk Factors for Hypoglycemia The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin [see Clinical Pharmacology ( 12.2 )] and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect over time of ONSWIK may vary among different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors that may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions ( 7 ) ] . Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations ( 8.6 , 8.7 )]. Risk Mitigation Strategies for Hypoglycemia Educate patients and caregivers to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended. 5.4 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions ( 5.3 )] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see Adverse Reactions ( 6.1 )]. The risk of hyperglycemia may be increased during the first four to six weeks of titration, especially if ONSWIK is initiated without the one-time starting dose [see Dosage and Administration ( 2.3 , 2.4 ), Clinical Pharmacology ( 12.2 , 12.3 )] . Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed [see Dosage and Administration ( 2.3 , 2.4 )]. 5.5 Hypersensitivity Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including ONSWIK [see Adverse Reactions ( 6.1 )] . If hypersensitivity reactions occur, discontinue ONSWIK; treat per standard of care and monitor until symptoms and signs resolve. ONSWIK is contraindicated in patients who have had hypersensitivity reactions to insulin efsitora alfa-gobe or any of the excipients in ONSWIK [see Contraindications ( 4 )] . 5.6 Hypokalemia All insulins, including ONSWIK, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations) and treat if indicated. 5.7 Never Share an ONSWIK Prefilled Pen Between Patients ONSWIK prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens. 5.8 Fluid Retention and Heart Failure with Concomitant Use of PPAR-Gamma Agonists Thiazolidinediones (TZDs), which are peroxisome proliferator activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including ONSWIK and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are described below or elsewhere in the prescribing information: Hypoglycemia Due to Medication Errors and Accidental Overdose [see Warnings and Precautions ( 5.1 )]. Severe Hypoglycemia in Patients with Type 1 Diabetes Mellitus [see Warnings and Precautions ( 5.2 )] . Hypoglycemia [see Warnings and Precautions ( 5.3 )] . Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] . Hypokalemia [see Warnings and Precautions ( 5.6 )]. Common adverse reactions include hypoglycemia, hypersensitivity reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of ONSWIK was evaluated in four clinical trials involving 1,883 adults with type 2 diabetes mellitus exposed to ONSWIK, with a mean exposure duration of 372 days [see Clinical Studies ( 14 )] . The mean age was 59 years, the mean duration of diabetes was 13 years, 55% were male, 63% were White, 21% were Asian, 10% were American Indian or Alaska Native, 5% were Black or African American, and 45% were Hispanic. The mean BMI was 31 kg/m 2 and the mean HbA1c at baseline was 8.1%. Common Adverse Reactions Hypoglycemia Hypoglycemia is the most common adverse reaction in patients using insulin, including ONSWIK. The frequency of reported hypoglycemia depends on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing the frequency of hypoglycemia in clinical trials for ONSWIK with the frequency of hypoglycemia for other products may be misleading and may not be representative of hypoglycemia frequencies that occur in clinical practice. In clinical trials [see Clinical Studies ( 14 )], events of severe hypoglycemia (level 3) were defined as an episode associated with severe cognitive impairment requiring external assistance for recovery. Hypoglycemia episodes with a glucose level below 54 mg/dL with or without associated symptoms (level 2 hypoglycemia) were also assessed in patients with type 2 diabetes mellitus. In clinical trials in patients with type 2 diabetes mellitus, the proportions of adults treated with ONSWIK who experienced at least one episode of level 3 and/or level 2 hypoglycemia in clinical trials are shown in Table 4 . Table 4: Proportion (%) of Patients with Type 2 Diabetes Mellitus Experiencing at Least One Episode of Level 3 (Severe) and/or Level 2 Hypoglycemia in Clinical Trials a Level 3 hypoglycemia: episode associated with severe cognitive impairment requiring external assistance for recovery. b Level 2 hypoglycemia: an episode where a self-measured glucose was below 54 mg/dL, with or without the presence of hypoglycemic symptoms. Trial 1 Insulin Naïve Adults on Fixed-Dosage Titration (0-52 weeks) N=397 Trial 2 Insulin Naïve Adults on Flexible-Dosage Titration (0-52 weeks) N=466 Trial 3 Adults Previously Treated with Daily Basal Insulin (0-78 weeks) N=655 Trial 4 Adults Previously Treated with Daily Basal and Mealtime Insulin (0-26 weeks) N=365 Level 3 hypoglycemia a 0.3 0 0.9 1.4 Level 3 and/or Level 2 hypoglycemia b 25.9 27.9 40.9 55.6 Insulin Initiation and Intensification of Glucose Control Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy. Allergic Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin, including ONSWIK. Hypersensitivity reactions were reported in adults with type 2 diabetes mellitus treated with ONSWIK: contact dermatitis (0.7%), rash (0.7%), dermatitis (0.7%), hypersensitivity (0.6%), pruritus (0.6%), eczema (0.6%) and allergic rhinitis (0.5%). Lipodystrophy Long-term use of insulin, including ONSWIK, can cause lipodystrophy at the site of repeated insulin injections. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue) and may affect insulin absorption [see Dosage and Administration ( 2.2 )]. Lipodystrophy was reported in 0.3% of adults with type 2 diabetes mellitus treated with ONSWIK. Injection Site Reactions Adults with type 2 diabetes mellitus taking ONSWIK have experienced redness, hardening, pain, bruising, swelling or itching at the site of ONSWIK injection. Injection site reactions occurred in 1.4% of adults with type 2 diabetes mellitus treated with ONSWIK. No patients treated with ONSWIK in the clinical trials discontinued ONSWIK due to injection site-related reactions. Weight Gain Weight gain can occur with insulin therapy, including ONSWIK, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria. Adults with type 2 diabetes mellitus treated with ONSWIK with or without mealtime insulin therapy gained an average of 1.9 to 3.2 kg after 26 weeks of treatment. Adults with type 2 diabetes mellitus treated with ONSWIK without mealtime insulin therapy gained an average of 2.1 to 3.9 kg after 52 weeks of treatment. Peripheral Edema ONSWIK may cause sodium retention and edema. Peripheral edema occurred in 1.6% of adults with type 2 diabetes mellitus treated with ONSWIK.

adverse reactions table

<table ID="t4" width="100%"> <caption>Table 4: Proportion (%) of Patients with Type 2 Diabetes Mellitus Experiencing at Least One Episode of Level 3 (Severe) and/or Level 2 Hypoglycemia in Clinical Trials </caption> <col width="21.380%" align="left"/> <col width="19.160%" align="left"/> <col width="20.380%" align="left"/> <col width="18.940%" align="left"/> <col width="20.140%" align="left"/> <tfoot> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Level 3 hypoglycemia: episode associated with severe cognitive impairment requiring external assistance for recovery. </paragraph> </td> </tr> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> Level 2 hypoglycemia: an episode where a self-measured glucose was below 54 mg/dL, with or without the presence of hypoglycemic symptoms. </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/> <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Trial 1</content> <content styleCode="bold">Insulin Na&#xEF;ve Adults on Fixed-Dosage Titration (0-52 weeks)</content> <content styleCode="bold">N=397</content> </td> <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Trial 2</content> <content styleCode="bold">Insulin Na&#xEF;ve Adults on Flexible-Dosage Titration</content> <content styleCode="bold">(0-52 weeks)</content> <content styleCode="bold">N=466</content> </td> <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Trial 3</content> <content styleCode="bold">Adults Previously Treated with Daily Basal Insulin</content> <content styleCode="bold">(0-78 weeks)</content> <content styleCode="bold">N=655</content> </td> <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Trial 4</content> <content styleCode="bold">Adults Previously Treated with Daily Basal and Mealtime Insulin</content> <content styleCode="bold">(0-26 weeks)</content> <content styleCode="bold">N=365</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Level 3 hypoglycemia<sup>a</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.4 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Level 3 and/or Level 2 hypoglycemia<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">25.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">27.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">40.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">55.6 </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.